Valuation: Roche Holding AG

Market Cap 266B 330B 289B 246B 463B 31,822B 473B 3,185B 1,253B 15,585B 1,241B 1,214B 53,652B P/E 2026 *
17.9x
P/E 2027 * 16.6x
Enterprise Value 277B 344B 300B 255B 481B 33,083B 492B 3,311B 1,302B 16,203B 1,290B 1,262B 55,777B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 4.14x
Free-Float
88.78%
Yield 2026 *
3%
Yield 2027 * 3.07%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 330B
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+1.41%+0.58%+33.92%+47.20% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
-0.36%+3.64%+1.91%-30.15% 143B
Average -0.14%+1.02%+25.01%+49.74% 376.38B
Weighted average by Cap. +0.09%+0.25%+36.99%+82.34%

Financials

2026 *2027 *
Net sales 62.6B 77.63B 67.84B 57.7B 109B 7,476B 111B 748B 294B 3,661B 292B 285B 12,604B 65.29B 80.96B 70.75B 60.18B 113B 7,796B 116B 780B 307B 3,818B 304B 297B 13,145B
Net income 15.22B 18.88B 16.5B 14.03B 26.45B 1,818B 27.04B 182B 71.58B 890B 70.9B 69.35B 3,065B 16.35B 20.27B 17.72B 15.07B 28.4B 1,952B 29.03B 195B 76.85B 956B 76.13B 74.46B 3,291B
Net Debt 10.56B 13.09B 11.44B 9.73B 18.34B 1,261B 18.75B 126B 49.62B 617B 49.16B 48.08B 2,125B 3.92B 4.86B 4.24B 3.61B 6.8B 468B 6.95B 46.8B 18.41B 229B 18.23B 17.83B 788B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA